VIR
VIR
NASDAQ · Biotechnology

Vir Biotechnology Inc

$10.88
+0.28 (+2.64%)
Financial Highlights (FY 2026)
Revenue
85.95M
Net Income
-549,124,052
Gross Margin
100.0%
Profit Margin
-638.9%
Rev Growth
-65.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 100.0% 41.4% 41.4%
Operating Margin -699.2% -629.3% -31.7% -35.1%
Profit Margin -638.9% -606.9% -27.2% -30.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 85.95M 246.41M 113.39M 105.81M
Gross Profit 85.91M 246.31M 46.97M 43.83M
Operating Income -600,936,777 -1,550,582,280 -35,981,507 -37,098,247
Net Income -549,124,052 -1,416,891,189 -30,823,495 -32,439,743
Gross Margin 100.0% 100.0% 41.4% 41.4%
Operating Margin -699.2% -629.3% -31.7% -35.1%
Profit Margin -638.9% -606.9% -27.2% -30.7%
Rev Growth -65.1% -65.1% +24.3% +5.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 432.19M 355.41M
Total Equity 459.65M 428.15M
D/E Ratio 0.94 0.83
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -600,460,612 -1,635,428,845 -42,153,177 -39,538,454
Free Cash Flow -22,930,380 -17,215,226